Functional data has shown that miR-637 is one of the effective regulators of HER2 signaling; in HER2-positive trastuzumab non-responsive cell lines, miR-637 was efficient to inhibit breast cancer cell growth [61]. This evidence concerns the gene ERBB2 and breast carcinoma.